Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
As 2017 came to close, The American Journal of Managed Care® (AJMC®) asked readers to weigh in on the events they believed had the greatest impact on managed care during the year. As the votes came in, it was clear that what happens in Washington, DC, matters—and that Capitol Hill policy makers will continue to make a difference in 2018.
Adapting payment models to reward outcomes is key to making lifestyle change fit into a managed care framework, several articles find.
The spending bill featured a waiver to avoid Medicare cuts in 2018, before voters to go to the polls in the midterm elections.
A short film supported by the makers of Stiolto Respimat shows the day-to-day life of 3 patients with COPD.
An interview with one of the authors of a large observational study that has seen findings consistent with recent cardiovascular outcomes trials in SGLT2 inhibitors.
A least one US payer, CareMore, has a program to combat loneliness in seniors to prevent chronic disease and other health problems.
Changes to CMS regulations and a post that became a social media phenomenon top the list.
What the CEO of the American Association for the Advancement of Science thinks about the current controversy.
On the plus side, a partnership with the American Medical Association appears to have contributed to a rise in provider referrals to lifestyle modification programs.
The payment reform movement has changed the thinking about what can be done for patients with diabetes and heart failure, for the good of patients.
New companies are finding patients for clinical trials in remote locations and trimming months off the enrollment process.
The cost of insulin has been a major policy issue in recent years. FDA Commissioner Scott Gottlieb, MD, said the approval of a new choice in insulin was a sign of his commitment to giving patients lower-cost options.
Both Don Berwick, MD, MPP, and Jerry Avorn, MD, argue that staying silent in the current climate is a choice, and not a good one for physicians.
The American Diabetes Association update has recommendations that affect liraglutide, canagliflozin, and empagliflozin.
Infantile spasms are hard to diagnose, which can lead to treatment delays, according to the study authors.
Semaglutide, Novo Nordisk’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes (T2D), received FDA approval Tuesday, after beating its rival in a head-to-head trial and coming to the approval process with proof of cardiovascular benefits already in hand.
Sanofi’s newest insulin met its primary objective in a large head-to-head trial that compared it with its chief competitor.
Researchers at Duke University found there is substantial room for improvement in providing consumers with ready access to healthcare prices online.
The FDA update was based on results of the FOURIER trial, which showed the drug reduced the risk of heart attacks, strokes, and revascularizations in high-risk patients.
Scaling back the Comprehensive Care for Joint Replacement model and canceling an expansion proposed under the Obama administration represents a shift in philosophy from mandatory to voluntary bundled payment models. But some say that commercial payers and employers will demand change no matter what CMS does.
Liver and endometrial cancer accounted for high numbers of new cases; increases of these cancer types have been attributed to rising rates of diabetes and obesity.
The review period in the report bridged a public scandal at the VA that forced the resignation of a former Cabinet secretary.
The research shows that giving patients support to keep weight off after surgery is key to maintaining diabetes remission.
Chief Togetherness Officer Robin Caruso, LCSW, highlights early successes of CareMore's program to address lonelineness in the senior population.
The Beyond A1C movement seeks regulatory and clinical are frameworks that recognize the day-to-day measures that matter to patients, such as how often they experience hypoglycemia.
The Coverage2Control campaign has worked to convince payers of the value of life-saving technology and the need to control out-of-pocket costs.
Federal regulators are asking for information that will get to the bottom of how drug discounting between pharmaceutical companies and health plans affect what seniors pay at the pharmacy counter.
The evolution of the navigator role has been an important development in cancer care, according to panelists who offered various perspectives on helping patients along the cancer journey.
The first major update since 2003 was announced this week during the 2017 American Heart Association Scientific Sessions.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
